Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer (OLCSG1303)
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2017
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Dec 2017 Status changed from recruiting to completed.
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
- 12 Sep 2017 Primary endpoint (Objective clinical response rate) has not been met, according to results presented at the 42nd European Society for Medical Oncology Congress.